NBL1 marker tied to end-stage renal disease in patients with diabetes
Aug. 18, 2022
There is a need of better markers that reflect key mechanisms involved in diabetic kidney disease (DKD). In a new study, investigators have identified increased concentrations of neuroblastoma suppressor of tumorigenicity 1 (NBL1) as a strong and independent predictor of progression to end-stage kidney disease (ESKD) in patients with diabetes.